Botulinum toxin manufacturers

About botulinum toxin

Botulinum toxin manufacturers include AbbVie (Botox), Ipsen (Dysport), Merz (Xeomin), and Korean producers such as Daewoong, Hugel and Medytox, plus Chinese and other regional makers. Botulinum toxin is a purified neurotoxin from Clostridium botulinum that temporarily blocks nerve signals to muscles and glands. It is used for medical conditions such as spasticity, dystonia, chronic migraine and overactive bladder, and for cosmetic treatment of facial lines. Pharmaceutical companies can source botulinum toxin products through out-licensing, supply or regional distribution.

Botulinum toxin key facts

Botulinum toxin manufacturers and licensing history

Botulinum toxin type A was first approved in the US in 1989 for eye muscle disorders. Allergan developed it as Botox and later Botox Cosmetic, and AbbVie acquired Allergan in 2020. Ipsen's Dysport and Merz's Xeomin followed, the latter without complexing proteins.

Korean companies became major producers. Daewoong's toxin is sold in the US as Jeuveau through Evolus. Hugel's letibotulinumtoxinA received US approval as Letybo in 2024, and Medytox sells Meditoxin and other products. Revance's long-acting Daxxify, approved in 2022, is now owned by Crown Laboratories. China has domestic producers, and Galderma has developed a ready-to-use liquid toxin.

Botulinum toxin is a highly potent biologic and a controlled select agent in many countries. Buyers should confirm the strain, manufacturing biosafety, GMP status, potency assay and regulatory history before choosing a partner.

Botulinum toxin dosage forms and dossier types

Botulinum toxin is supplied as powder for reconstitution or as ready-to-use solution, labelled in product-specific units.

Botulinum toxin regulatory and patent status

Each botulinum toxin product is approved separately as a biologic, with its own clinical data and unit potency. There are no generic or biosimilar botulinum toxins in the US or EU. Labels carry warnings about distant spread of toxin effect, which can cause swallowing and breathing problems. Some newer formulations and manufacturing processes are patent-protected.

Botulinum toxin mechanism of action and therapeutic use

Botulinum toxin blocks the release of acetylcholine at nerve endings, which temporarily weakens the injected muscles or reduces gland secretion. The effect lasts about 3–6 months. It is used medically for spasticity, dystonia, blepharospasm, chronic migraine, overactive bladder and excessive sweating, and cosmetically for facial lines.

Botulinum toxin licensing and sourcing

Botulinum toxin suppliers and licensing partners typically offer regional distribution, out-licensing or co-development. Buyers usually compare GMP status, regulatory approvals, clinical data, indications and territory availability. Current offers and supplier contacts are listed among the botulinum toxin manufacturers on Pipelinepharma.

Frequently asked questions about botulinum toxin

Who are the main botulinum toxin manufacturers? AbbVie (Botox), Ipsen (Dysport) and Merz (Xeomin) are the main Western producers. Korean companies such as Daewoong, Hugel and Medytox are also major suppliers.

Are botulinum toxin products interchangeable? No. Each product has its own unit potency, so doses cannot be converted directly between brands.

Is there a generic or biosimilar botulinum toxin? No. Each botulinum toxin is approved separately as a biologic with its own clinical data.

What is botulinum toxin used for? Botulinum toxin is used for spasticity, dystonia, chronic migraine, overactive bladder, excessive sweating and cosmetic facial lines.

How long does botulinum toxin last? The effect usually lasts about 3–6 months, depending on the product and indication.